Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here, we report details of a 29-year-old woman treated successfully by donor lymphocyte infusions (DLIs) following allogeneic HSCT for acquired refractory relapsed PRCA. The nonmyeloablative conditioning regimen consisted of cyclophosphamide 60 mg/kg/day for 2 days and fludarabine 30 mg/m 2 daily for 4 days. Haematopoiesis was still completely 'recipient' 1 month after allo-HSCT, but progressed to full donor engraftment after three doses of 'escalating' DLI. The possible role of a graft-versus-autoimmunity effect induced by allogeneic HSCT followed by DLI infusions in the treatment of the disease is discussed.
autoimmunity; allogeneic nonmyeloablative stem cell transplant; DLI Acquired pure red cell aplasia (PRCA) is an infrequent autoimmune myelopathy that affects selectively marrow erythropoiesis. Although infection with the human parvovirus B19 may cause persistent erythroid aplasia in immunocompromised patients, 'primary' PRCA is more usually due to a variable combination of T (cytotoxic) and B (humoral) effector mechanisms. There is no doubt, however, that acquired PRCA is a typical example of an autoimmune myelopathy. 1 Immunosuppressive treatment of PRCA generally induces remissions, but in most cases the disease recurs. 2 Haematopoietic stem cell transplantation (HSCT), either autologous or allogeneic, is now performed for a wide spectrum of severe autoimmune diseases (SADs) that are refractory to or relapse repeatedly following routine immunosuppressive therapy. 3, 4 Allogeneic HSCT is clearly the most effective procedure because it supplies a naive immune system even in concordant twins and also provides a powerful 'graft-versus-autoimmunity' (GVA) effect. 5, 6 Here, we report a case of PRCA that relapsed after both autologous and allogeneic transplants, but went into complete long-term remission with full donor chimerism following donor lymphocyte infusions (DLIs).
Case report
A 29-year-old woman was diagnosed with chronic acquired PRCA. Treatment with steroids and erythropoietin induced a complete remission (Hb: 12 g/dl). After 2 years, she relapsed and was resistant to conventional immunosuppressive therapies. Owing to severe anaemia and high transfusion requirement, an autotransplant action procedure was recommended. The patient was mobilized with cyclophosphamide (Cy) 4 g/m 2 followed by G-CSF 300 mg/ day. No erythropoietic response followed the mobilization procedure. The leukapheresis product was selected with the Isolex 300i device (Baxter/Nexell) using CD34 monoclonal antibody conjugated with magnetic beads. A second unmanipulated leukapheresis product was cryopreserved as back up. The patient was conditioned with Cy 50 mg/kg/ day i.v. on days À6 and À5, antithymocyte globulin i.v. and methyl prednisolone 1 g/day i.v. on days À4 to À2. 7 A CR was obtained (Hb: 11.8 g/dl), but the patient relapsed at day þ 104 (Hb: 8.0 g/dl). The bone marrow aspirate showed normal myelopoiesis and megakaryocytopoiesis but extreme erythroid hypoplasia. Once again the patient received immunosuppressive treatment associated with erythropoietin, but there was no response and the high transfusion requirement continued. After informed consent and the local Ethical Committee approval, the patient underwent allogeneic peripheral blood precursor cell transplant from her HLA-identical brother. Mixed chimerism (55% of metaphases with 46,XX karyotype) was noted 5 months post transplant. Cytogenetic analysis at 12, 15 and 24 months post transplant showed full donor karyotype (male). At day þ 1621 after allotransplant, the patient remains well and in complete remission. She has no signs or symptoms of GVHD.
Discussion
Autologous HSCT in SAD is thought to act through two main mechanisms: powerful immunosuppression and possible 'resetting' of the immune system. [5] [6] [7] The first component may well be the most important, and in this respect there is no great difference from the treatment with high doses of Cy not followed by autologous cell rescue. 8 However, the beneficial effect of an allograft is attributable to the combination of immunosuppression by the conditioning regimen and the immunological reaction against host cells, usually expressed as a graft-versus-leukaemia (GVL) effect. This adoptive allogeneic cell therapy mediated by DLI induces lasting complete remissions by an immune-mediated GVL without intensive chemotherapy, most prominently for patients with CML. In an analogous manner, it has been postulated that allo-HSCT may also mediate a 'GVA' effect by gradually eradicating T and B autoreactive lymphocytes. 5, 6, 9 A conditioning regimen including Flu-Cy, besides achieving a reduction in transplant-related mortality, allows the administration of infusions of allogeneic donor T cells capable of inducing GVL and possibly GVA.
In this female patient with adult acquired PRCA first immunosuppressive treatment and subsequently autologous HSCT produced remissions, but in each case the patient relapsed. We believe that this is the first report of primary acquired relapsing PRCA successfully treated by allogeneic SCT followed by DLI associated with full donor haematopoiesis. Karyotypic analysis showed female metaphases 1 month after the conditioning regimen, while a CR with full donor (male) haematopoiesis was achieved after DLI infusions, providing an 'indirect clinical' evidence of the immune pathogenesis of PRCA. In addition, this case supports the recent suggestion that clinical tolerance may be achieved in some patients through mixed or full donor chimerism induced by allogeneic transplants with lowintensity conditioning regimens, finally resulting in abrogation of autoimmunity. 5, 10 In conclusion, allo-HSCT with nonmyeloablative regimen, followed if necessary by DLI infusions, may be a valuable approach for SAD patients with a very poor prognosis, including patients with relapsing/refractory PRCA. 
